Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT01483274 Withdrawn - Clinical trials for Acute Myelogenous Leukemia

Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation

AML
Start date: March 2015
Phase: Phase 1
Study type: Interventional

Patients with Acute Myelogenous Leukemia (AML) who relapse after an allogeneic stem cell transplant cell receive decitabine to up regulate cancer antigen expression, followed by a donor lymphocyte infusion and an autologous dendritic cell (DC). Vaccine Dendritic cells are pulsed with overlapping peptides derived from MAGE-A1, MAGE-A3, and NY-ESO-1.

NCT ID: NCT01478074 Withdrawn - Clinical trials for Acute Myeloid Leukemia

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Start date: November 2011
Phase: Phase 1
Study type: Interventional

This is a single-center open-label phase I clinical trial of delivering haploidentical natural killer (NK) cells matured ex vivo with ALT-801 followed by intravenous infusions of ALT-801 in patients with relapsed/refractory Acute Myeloid Leukemia (AML). The study will be conducted at M.D. Anderson Cancer Center (MDACC) and MDACC Children's Cancer Hospital in Houston, Texas.

NCT ID: NCT01477606 Completed - Clinical trials for Acute Myeloid Leukemia

Protocol in Acute Myeloid Leukemia With FLT3-ITD

Start date: May 2012
Phase: Phase 2
Study type: Interventional

This is a phase II, single-arm, open-label, multi-center study in adult patients with Acute Myeloid Leukemia (AML) and FLT3-ITD as defined in inclusion/exclusion criteria. The primary efficacy object is to evaluate the impact of midostaurin given in combination with intensive induction, consolidation including allogeneic hematopoietic stem cell transplantation and single agent maintenance therapy on event-free survival (EFS) in adult patients with AML exhibiting a FLT3-ITD. Sample size: 440 patients The treatment duration of an individual patient is between 18 and 24 months. Duration of the study for an individual patient including treatment (induction, consolidation [chemotherapy or allogeneic SCT], maintenance and follow-up period: Maximum 8 years

NCT ID: NCT01475370 Completed - Clinical trials for Acute Myeloid Leukemia

Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)

Start date: January 24, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety of OCV-501 in patients with AML who completed the Study 311-10-001 and were judged that there was no relapse by any inspections in the end of the study.

NCT ID: NCT01475110 Completed - Clinical trials for Chronic Myeloid Leukaemia

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib

CML0609
Start date: September 13, 2012
Phase:
Study type: Observational

The GIMEMA CML Working Party promotes an observational (retrospective and perspective) study of Imatinib-resistant or intolerant CML patients treated with Nilotinib in Italy. Enrollment will include all patients who started Nilotinib between January 2005 and December 2012. Patients will be followed for 4 years since treatment start. After this time, survival data, disease status and treatment will be recorded at 6-months-interval. This study will help the definition of guidelines for a proper management of Nilotinib in any-phase CML patients.

NCT ID: NCT01474681 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Start date: January 9, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.

NCT ID: NCT01471444 Completed - Leukemia Clinical Trials

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Start date: November 2, 2011
Phase: Phase 3
Study type: Interventional

The goal of this clinical research study is to learn if combining busulfan with clofarabine and fludarabine can help control the disease better than the previous standard method (using busulfan and fludarabine alone) in patients with AML or MDS. The safety of this combination therapy will also be studied.

NCT ID: NCT01468467 Completed - Clinical trials for Leukemia, Myeloid, Acute

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

Start date: April 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to define a safe dose of AC220 when given as maintenance therapy after treatment with an allogeneic stem cell transplant.

NCT ID: NCT01465386 Terminated - Clinical trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Start date: November 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well bortezomib works in treating patients with high-risk acute myeloid leukemia (AML) in remission. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

NCT ID: NCT01464411 Recruiting - Clinical trials for Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan

D-First
Start date: July 2011
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate effectiveness of Dasatinib as the first line therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase in Japan.